Goswami M, Vandenberg K, Han S, Wang L, Singh B, Weiss T, et al. Identification of TP53RK Binding Protein (TPRKB) dependency in TP53-deficient cancers. Mol Cancer Res. 2019;: pubmed publisher

Hashimoto A, Hashimoto S, Sugino H, Yoshikawa A, Onodera Y, Handa H, et al. ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance. Oncogenesis. 2016;5:e259 pubmed publisher

Hashimoto A, Oikawa T, Hashimoto S, Sugino H, Yoshikawa A, Otsuka Y, et al. P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. J Cell Biol. 2016;213:81-95 pubmed publisher

Junk D, Vrba L, Watts G, Oshiro M, Martinez J, Futscher B. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia. 2008;10:450-61 pubmed